OBRIEN JAMES J /KY
OBRIEN JAMES J /KY's purchase track record
OBRIEN JAMES J /KY has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/27/2025 | EMN | $100K | -9.9% | +12.5% | +7.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Albemarle Faces Q3 Earnings Test Amid Mixed Analyst Views. Albemarle is set to report third-quarter earnings on November 4, 2026, a key date for the battery materials sector. While some analysts note improving fundamentals, Mizuho recently lowered its price target to $130 and maintained a Neutral rating. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite recent positive news about supply chain resilience.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Humana to drop 37 PPOs for 2027 Medicare Advantage plans. Humana announced it will discontinue 37 Preferred Provider Organization (PPO) plans for the 2027 Medicare Advantage enrollment period. The company noted that affected members may qualify for a Medigap open enrollment window without health questions. This structural change impacts the company's product lineup and member retention strategies for the upcoming year.
Transaction History
| EMN | ▼ Sell | Gift | 5,378 | $0 | 9/2/2026 | View on chart |
| EMN | ▼ Sell | Gift | 2,482 | $0 | 9/2/2026 | View on chart |
| EMN | ▼ Sell | Gift | 7,860 | $0 | 9/2/2026 | View on chart |
| EMN | ▲ Buy | Grant | 1,628 | $0 | 5/7/2026 | View on chart |
| EMN | ▲ Buy | Open Market | 1,450 | $100K | 8/27/2025 | View on chart |
| ALB | ▲ Buy | Grant | 2,725 | $0 | 7/1/2025 | View on chart |
| ALB | ▲ Buy | Grant | 37 | $0 | 7/1/2025 | View on chart |
| EMN | ▲ Buy | Grant | 1,575 | $0 | 5/1/2025 | View on chart |
| ALB | ▲ Buy | Grant | 1,750 | $0 | 7/1/2024 | View on chart |
| ALB | ▲ Buy | Grant | 10 | $0 | 7/1/2024 | View on chart |
| EMN | ▲ Buy | Grant | 1,252 | $0 | 5/2/2024 | View on chart |
| ALB | ▲ Buy | Grant | 750 | $0 | 7/3/2023 | View on chart |
| EMN | ▲ Buy | Grant | 1,396 | $0 | 5/4/2023 | View on chart |
| HUM | ▲ Buy | Grant | 380 | $0 | 1/3/2023 | View on chart |
| ALB | ▲ Buy | Grant | 731 | $0 | 7/1/2022 | View on chart |
| HUM | ▲ Buy | Grant | 412 | $0 | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Eastman Chemical faces lower price targets from UBS, Mizuho, Citi
Three major banks recently lowered their price targets for Eastman Chemical, citing ongoing industry pressures. Despite these reductions, all firms maintained positive ratings on the stock. The company continues to offer a dividend yield of 3.86%, which remains a key feature for income-focused investors.
Eastman Chemical faces lower price targets from UBS, Mizuho, Citi. Three major banks recently lowered their price targets for Eastman Chemical, citing ongoing industry pressures. Despite these reductions, all firms maintained positive ratings on the stock. The company continues to offer a dividend yield of 3.86%, which remains a key feature for income-focused investors.